Evidence map›Paper›PMID 40645983›Full record

ArticleNature communications2025

Forced expression of MSR repeat transcripts above a threshold limit breaks heterochromatin organisation.

Reagan W Ching, Kalina M Świst-Rosowska, Galina Erikson, Birgit Koschorz, Bettina Engist, Thomas Jenuwein

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reagan W ChingMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany. ching@ie-freiburg.mpg.de.ORCID http://orcid.org/0000-0001-7452-6177
Kalina M Świst-RosowskaMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.
Galina EriksonMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.
Birgit KoschorzMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.
Bettina EngistMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.
Thomas JenuweinMax Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany. jenuwein@ie-freiburg.mpg.de.ORCID http://orcid.org/0000-0002-0470-0421

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) CRC992 'MEDEP'
6 · The paper itself

Abstract

Mouse heterochromatin is characterised by transcriptionally competent major satellite repeat (MSR) sequences and it has been proposed that MSR RNA contributes to the integrity of heterochromatin. We establish an inducible dCas9-effector system in mouse embryonic fibroblasts, where we can modulate MSR transcription through the targeting of a dCas9-Repressor or a dCas9-Activator. With this system, we can define a threshold limit of >300-fold deregulation of MSR transcript levels, above which the structural organisation of heterochromatin becomes disrupted. MEF cells expressing MSR RNA above this threshold limit are not viable and the defects in heterochromatin organisation and chromosome segregation cannot be reverted. This study highlights the importance of restricting MSR RNA output to maintain heterochromatin integrity and relates MSR transcript levels to either physiological or pathological conditions. It also reveals that the structural organisation of heterochromatin is governed by the transcriptional chromatin state and associated MSR RNA of the MSR repeats.

Indexed as

DNA, SatelliteHeterochromatinAnimalsChromosome SegregationCRISPR-Cas SystemsFibroblastsMiceTranscription, GeneticDNA, SatelliteHeterochromatin

Identifiers

PMID40645983
PMCPMC12254318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.